PTPRC and neoplasm: We performed scRNA-seq analysis on CD45+ cells isolated from the tumor tissues of control group (n = 10,659 cells sequenced, coverage of 84 655 mean reads per cell) and the non-RFA side of the RFA-treated group (n = 8005 cells sequenced, coverage of 112,967 mean reads per cell).